Inactive Instrument

Highlights Mabvax Therapeutics Holdings Inc Nasdaq

Equities

US55414P5044

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

BioNTech Research and Development, Inc. completed the acquisition of substantially all assets from MabVax Therapeutics Holdings, Inc..	19-05-07	CI
Oncotelic Inc. cancelled the acquisition of MabVax Therapeutics Holdings, Inc. in a reverse merger transaction.	19-04-16	CI
BioNTech Research and Development, Inc. agreed to acquire substantially all assets from MabVax Therapeutics Holdings, Inc. for $2.3 million.	19-03-20	CI
Oncotelic Inc. signed a non-binding letter of intent to acquire MabVax Therapeutics Holdings, Inc. in a reverse merger transaction.	19-01-03	CI
MabVax Therapeutics Holdings, Inc. and Boehringer Ingelheim Sign Asset Purchase and License Agreement and Related Agreements for an Antibody Development Program Targeting Multiple Solid Tumor Cancers	18-07-09	CI
MabVax Therapeutics Holdings Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine	18-07-03	CI
MabVax Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2017	18-04-02	CI
MabVax Therapeutics Holdings, Inc. Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers	18-02-28	CI
Abvax Therapeutics Holdings, Inc. Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic Cancer	18-02-12	CI
MabVax Therapeutics Holdings, Inc. Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy	17-12-20	CI
MabVax Therapeutics Holdings, Inc. Announces Completion of Enrollment and Dosing in Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers	17-12-13	CI
MabVax Therapeutics Holdings, Inc. Therapeutics to Present Positive Development Study Results Enabling Manufacturing of Two Radionuclide Products for Phase 1 Clinical Trials at the 2017 AAPS Annual Meeting	17-11-13	CI
MabVax Therapeutics Provides Update on the MVT-5873 Phase 1 Clinical Program and Expansion of Preclinical Development Pipeline at the AACR-NCI-EORTC International Conference	17-10-31	CI
MabVax Therapeutics Holdings, Inc. Files New Patent Application on its Fully-Human Antibody Discoveries	17-10-24	CI
Mabvax Therapeutics Holdings, Inc Announces Initiation of Patient Enrollment in A Phase 1 Clinical Trial	17-10-11	CI
MabVax Therapeutics Commences Patient Dosing in MVT-1075 Radioimmunotherapy Phase 1 Clinical Trial for the Treatment of Pancreatic, Colon and Lung Cancers	17-06-27	CI
MabVax Therapeutics Holdings, Inc. Reports Results from Phase 1 Clinical Trial of ImmunoPET Imaging Agent, MVT-2163, for Patients with Locally Advanced or Metastatic Adenocarcinoma of the Pancreas or Other CA19-9 Positive Malignancies	17-06-14	CI
Mabvax Therapeutics Holdings, Inc. Signs Research Agreement with Memorial Sloan Kettering Cancer Center to Develop Novel CAR T-Cell Based Anti-Cancer Immunotherapies for Treatment of Pancreatic and Small Cell Lung Cancers	17-05-31	CI
MabVax Therapeutics Holdings, Inc. Announces Results from the Phase I Clinical Trial of Therapeutic Antibody MVT-5873	17-05-25	CI
MabVax Therapeutics Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	17-05-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mabvax Therapeutics Holdings Inc Nasdaq

Equities

US55414P5044

Highlights

Filters